Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses evolving options in first line treatment of ALK-Positive non-small cell lung cancer (NSCLC).

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer NSCLC.

1. Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss ALK marker testing.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss the treatment of stage 3 unresectable non-small cell lung cancer.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss treatment of early stage non-small cell lung cancer.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss Stage IIIA N2 Non-Small Cell Lung Cancer for Spanish-speaking patients and caregivers.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joins GRACE to discuss molecular marker testing for advanced NSCLC for Spanish speaking patients and caregivers.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, & Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss the response time on checkpoint inhibitors and the concept of pseudoprogression.